 Antimetabolites, Antineoplastic
"Antimetabolites, Antineoplastic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antimetabolites that are useful in cancer chemotherapy.
| Descriptor ID |
D000964
|
| MeSH Number(s) |
D27.505.519.186.144 D27.505.954.248.144 D27.888.569.042.030
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Antimetabolites, Antineoplastic".
Below are MeSH descriptors whose meaning is more specific than "Antimetabolites, Antineoplastic".
This graph shows the total number of publications written about "Antimetabolites, Antineoplastic" by people in this website by year, and whether "Antimetabolites, Antineoplastic" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 | | 1997 | 2 | 0 | 2 | | 1998 | 0 | 1 | 1 | | 1999 | 2 | 2 | 4 | | 2001 | 0 | 2 | 2 | | 2002 | 5 | 0 | 5 | | 2003 | 0 | 1 | 1 | | 2005 | 1 | 0 | 1 | | 2006 | 1 | 2 | 3 | | 2007 | 2 | 0 | 2 | | 2008 | 1 | 2 | 3 | | 2009 | 1 | 4 | 5 | | 2010 | 5 | 1 | 6 | | 2011 | 0 | 1 | 1 | | 2012 | 1 | 1 | 2 | | 2013 | 4 | 2 | 6 | | 2015 | 2 | 1 | 3 | | 2016 | 1 | 1 | 2 | | 2017 | 2 | 1 | 3 | | 2018 | 3 | 3 | 6 | | 2019 | 1 | 0 | 1 | | 2020 | 2 | 1 | 3 | | 2022 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Antimetabolites, Antineoplastic" by people in Profiles.
-
Orellana-Noia VM, Reed DR, McCook AA, Sen JM, Barlow CM, Malecek MK, Watkins M, Kahl BS, Spinner MA, Advani R, Voorhees TJ, Snow A, Grover NS, Ayers A, Romancik J, Liu Y, Huntington SF, Chavez JC, Saeed H, Lazaryan A, Raghunathan V, Spurgeon SE, Ollila TA, Del Prete C, Olszewski A, Ayers EC, Landsburg DJ, Echalier B, Lee J, Kamdar M, Caimi PF, Fu T, Liu J, David KA, Alharthy H, Law J, Karmali R, Shah H, Stephens DM, Major A, Rojek AE, Smith SM, Yellala A, Kallam A, Nakhoda S, Khan N, Sohail MA, Hill BT, Barrett-Campbell O, Lansigan F, Switchenko J, Cohen J, Portell CA. Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions. Blood. 2022 01 20; 139(3):413-423.
-
Dhar D, Raina K, Kumar D, Wempe MF, Bagby SM, Pitts TM, Orlicky DJ, Agarwal C, Messersmith WA, Agarwal R. Bitter melon juice intake with gemcitabine intervention circumvents resistance to gemcitabine in pancreatic patient-derived xenograft tumors. Mol Carcinog. 2020 10; 59(10):1227-1240.
-
Yang J, Wang J, Zhou H, Wang Y, Huang H, Jin H, Lou Q, Shah RJ, Zhang X. Endoscopic radiofrequency ablation plus a novel oral 5-fluorouracil compound versus radiofrequency ablation alone?for unresectable extrahepatic cholangiocarcinoma. Gastrointest Endosc. 2020 12; 92(6):1204-1212.e1.
-
Phillips CL, Lane A, Gerbing RB, Alonzo TA, Wilkey A, Radloff G, Lange B, Gamazon ER, Dolan ME, Davies SM. Genomic Variants of Cytarabine Sensitivity Associated with Treatment-Related Mortality in Pediatric AML: A Report from the Children's Oncology Group. Clin Cancer Res. 2020 06 15; 26(12):2891-2897.
-
Gasparetto M, Pei S, Minhajuddin M, Stevens B, Smith CA, Seligman P. Low ferroportin expression in AML is correlated with good risk cytogenetics, improved outcomes and increased sensitivity to chemotherapy. Leuk Res. 2019 05; 80:1-10.
-
Cortes JE, Heidel FH, Hellmann A, Fiedler W, Smith BD, Robak T, Montesinos P, Pollyea DA, DesJardins P, Ottmann O, Ma WW, Shaik MN, Laird AD, Zeremski M, O'Connell A, Chan G, Heuser M. Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome. Leukemia. 2019 02; 33(2):379-389.
-
Whittington MD, McQueen RB, Ollendorf DA, Kumar VM, Chapman RH, Tice JA, Pearson SD, Campbell JD. Long-term Survival and Value of Chimeric Antigen Receptor T-Cell Therapy for Pediatric Patients With Relapsed or Refractory Leukemia. JAMA Pediatr. 2018 12 01; 172(12):1161-1168.
-
Prince GT, Cameron MC, Fathi R, Alkousakis T. Topical 5-fluorouracil in dermatologic disease. Int J Dermatol. 2018 Oct; 57(10):1259-1264.
-
Murthy R, Borges VF, Conlin A, Chaves J, Chamberlain M, Gray T, Vo A, Hamilton E. Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b study. Lancet Oncol. 2018 07; 19(7):880-888.
-
Prince GT, Cameron MC, Fathi R, Alkousakis T. Intralesional and Laser-Assisted 5-Fluorouracil in Dermatologic Disease: A Systematic Review. J Drugs Dermatol. 2018 Mar 01; 17(3):274-280.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|